retatrutide phase 2 trial obesity Looking forward to when #retatrutide's 3 results will become available. There are are 4 planned TRIUMPH trials investigating retatrutide's efficacy in treating and its complications: #type2diabetes #cardiovascular disease Retatrutide, a GIP, GLP-1 and

quality standards, providing a safe and comprehensive approach to effective weight management and long-term metabolic health, designed to live in harmony with the body, not against it

Twenty-seven participants were randomised to liraglutide (n=13) or placebo (n=14)

The highly sensitive GLP-1 ELISA (Active 7-36) is for the quantification of bioactive GLP-1 (7-36) levels in human EDTA-plasma. Superior analytical sensitivity0.05 pmol/L Broad dynamic range0.6448 pmol/L Research Use Only

Missed your Ozempic shot

Recent observations and emerging research have raised concerns about increased tendon injuries and declining bone health in some individuals using GLP-1 therapies

- - - A new Oxford meta-analysis (P04.009, EASO 2025) confirms what many clinicians have observed: stopping GLP-1 receptor agonists often leads to rapid and near-complete weight regain within 12 years